[News] Research in Brief

Qian Wang and colleagues assessed the feasibility of HN2301, an engineered CD8 T-cell-targeted lipid nanoparticle encapsulating CD19 chimeric antigen receptor (CAR) messenger RNA, in five patients with refractory systemic lupus erythematosus (SLE). Patients received an infusion of HN2301 at a dose of 2 mg or 4 mg. CD8+ CD19 CAR T cells and CAR mRNA peaked at 6 h after infusion, decreasing to baseline levels within 2–3 days. Within 6 h after infusion, circulating B cells were substantially decreased in the two patients who received the 2 mg dose and were completely depleted for 7–10 days after administration in the three patients who received the 4 mg dose.